This program is designed to help NIH Phase II awardees transition their SBIR-STTR-developed products into the marketplace by providing companies with individualized assistance toward accomplishing their regulatory and commercialization goals.
- Exscien secures premises at 1044 East Chestnut Street in Louisville, Kentucky to house its future manufacturing and processing center. June 1, 2016
- Exscien Corporation is awarded support under the Commercialization Assistance Program (CAP) for NIH SBIR and STTR Phase II awardees. October 1, 2015
- Kentucky SBIR Matching Funds Program October 1, 2015
- Exscien receives a $3.2 million NIH SBIR Phase II grant related to the development of its fusion protein in the field of acute lung injury. July 1, 2015
- Exscien receives $150,000 NIH STTR Phase I grant for the development of its technology related to chromatin integration via novel minimal piggyback vectors. November 1, 2014